Pipeline

Project : MFA011

Indication : Oncology

Discovery Lead Optimization Preclinical Efficacy IND-enabling

MFA011 enables targeted delivery of IL-15 to tumor-associated immune cells, maximizing immune activation where it is needed most, by combining our proprietary anti-TIGIT antibody with an engineered IL-15 cytokine.

Learn more
Project : MFA031

Indication : Autoimmune Diseases, Transplantation

Discovery Lead Optimization Preclinical Efficacy IND-enabling

MFA031 is a first-in-class TIGIT agonist–IL-10 fusion therapeutic designed to restore immune balance through targeted immune regulation.

Learn more
Project : MFA041

Indication : Autoimmune Diseases

Discovery Lead Optimization Preclinical Efficacy IND-enabling
Platform: MediLink™

A Plug-and-Play Platform for Precision Immunology

Discovery Lead Optimization Preclinical Efficacy IND-enabling

MediLink is our proprietary plug-and-play platform for the development of precision immune therapeutics. By seamlessly integrating target-specific antibodies with engineered cytokines, the platform enables the development of novel therapeutic modalities with programmable biological functions.

Platform: MediKine™

Proprietary Engineered Cytokines

Discovery Lead Optimization Preclinical Efficacy CMC development IND-enabling Phase I

MediKine™ is MMB’s proprietary engineered cytokine platform designed to optimize cytokine activity, improve safety, and extend therapeutic durability. By precisely controlling the strength, duration, and quality of cytokine signaling, MediKine™ enables targeted immune modulation with an improved therapeutic window.

Pipeline Indication Modality Discovery Lead Optimization Preclinical Efficacy IND-enabling
MediLink™ Programs
MFA011 Cancer Fusion Ab
MFA031 Autoimmune Diseases,
Transplantation		 Fusion Ab
MFA041 Autoimmune Diseases Fusion Ab
Platforms
MediLink™
Platform		 Cancer,
Autoimmune Diseases		 Fusion Ab
MediKine™
Platform		 Cancer,
AutoimmuneDiseases		 Fusion Ab